确定体细胞肿瘤突变是否可靶向以及获得靶向治疗的选择。

Q1 Nursing
S. Bruinooge, Shimere Sherwood, S. Grubbs, R. Schilsky
{"title":"确定体细胞肿瘤突变是否可靶向以及获得靶向治疗的选择。","authors":"S. Bruinooge, Shimere Sherwood, S. Grubbs, R. Schilsky","doi":"10.1200/JOP.19.00262","DOIUrl":null,"url":null,"abstract":"Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.","PeriodicalId":54273,"journal":{"name":"Journal of Oncology Practice","volume":"1 1","pages":"JOP1900262"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1200/JOP.19.00262","citationCount":"7","resultStr":"{\"title\":\"Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.\",\"authors\":\"S. Bruinooge, Shimere Sherwood, S. Grubbs, R. Schilsky\",\"doi\":\"10.1200/JOP.19.00262\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.\",\"PeriodicalId\":54273,\"journal\":{\"name\":\"Journal of Oncology Practice\",\"volume\":\"1 1\",\"pages\":\"JOP1900262\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1200/JOP.19.00262\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/JOP.19.00262\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/JOP.19.00262","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 7

摘要

癌症靶向治疗是通过阻断或干扰癌症细胞中的特定分子途径来影响癌症细胞生长的药物和生物制品。靶向药物的使用通常需要通过分子测试来验证患者的肿瘤是否含有作为药物靶点或可预测治疗益处的分子生物标志物。如果基因组突变与对潜在治疗的反应或耐药性有关,则可能在临床上可行。如果基因组测试揭示了一种可操作的改变,那么有几种选择可以用于靶向治疗。这篇文章旨在帮助临床医生确定肿瘤突变是否有可能通过上市或研究药物或生物产品进行治疗,并就如何获得感兴趣的产品提供指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Oncology Practice
Journal of Oncology Practice Nursing-Oncology (nursing)
CiteScore
4.60
自引率
0.00%
发文量
0
期刊介绍: Journal of Oncology Practice (JOP) provides necessary information and insights to keep oncology practice current on changes and challenges inherent in delivering quality oncology care. All content dealing with understanding the provision of care—the mechanics of practice—is the purview of JOP. JOP also addresses an expressed need of practicing physicians to have compressed, expert opinion addressing common clinical problems.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信